Cardiex Ltd
ASX:CDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (4.1), the stock would be worth AU$0.03 (0% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.1 | AU$0.03 |
0%
|
| 3-Year Average | 4.1 | AU$0.03 |
0%
|
| 5-Year Average | 4.2 | AU$0.03 |
+2%
|
| Industry Average | 2.4 | AU$0.02 |
-42%
|
| Country Average | 1.7 | AU$0.01 |
-58%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Cardiex Ltd
ASX:CDX
|
18.7m AUD | 4.1 | -1.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 10.9 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 2.2 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 3.1 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 1.5 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 2.3 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 4.7 | 43 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 1.2 | 18.4 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 14.5 | 41.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 1.2 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 4.4 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Cardiex Ltd
Glance View
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.
